This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights Eli Lilly, Linde, NextEra Energy, Honda Motor, Arthur J. Gallagher and Block
by Zacks Equity Research
Eli Lilly, Linde, NextEra Energy, Honda Motor, Arthur J. Gallagher and Block are included in this Analyst Blog.
Top Analyst Reports for Eli Lilly, Linde & NextEra Energy
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Linde plc (LIN) and NextEra Energy, Inc. (NEE).
Why Eli Lilly (LLY) Dipped More Than Broader Market Today
by Zacks Equity Research
Eli Lilly (LLY) reachead $628.91 at the closing of the latest trading day, reflecting a -0.89% change compared to its last close.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Bull of the Day: Regeneron Pharmaceuticals (REGN)
by Ethan Feller
The Biotechnology company enjoys a litany of bullish catalysts on the horizon
Zacks Investment Ideas feature highlights: Eli Lilly and Novartis
by Zacks Equity Research
Eli Lilly and Novartis have been highlighted in this Investment Ideas article.
These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High
by Bryan Hayes
As investors, our job isn't to predict an unknowable future.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and AstraZeneca
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Amgen and AstraZeneca are included in this Analyst Blog.
FDA Finds No Link Between Obesity Drugs and Suicidal Thoughts
by Kinjel Shah
The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.
Why Eli Lilly (LLY) Outpaced the Stock Market Today
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $630.19, moving +0.75% from the previous trading session.
Omega (OMGA) Up 95% on Obesity Drug Deal With Novo Nordisk
by Zacks Equity Research
Using Omega's (OMGA) proprietary technology platform, Novo Nordisk (NVO) intends to develop a novel therapeutic for obesity, which will enhance the body's metabolism activity to burn excess fats.
NVS or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
Lilly (LLY) Starts Website to Help Access Tirzepatide Drugs
by Zacks Equity Research
Eli Lilly's (LLY) digital pharmacy is expected to provide patients easy access to its FDA-approved tirzepatide medicines, Mounjaro and Zepbound.
Novo Nordisk (NVO) Up on $1.1B Research Deals With 2 Biotechs
by Zacks Equity Research
Novo Nordisk (NVO) gains 4% after signing $1.1 billion research collaboration agreements with two biotech companies to develop novel treatment approaches for cardiometabolic diseases.
Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals
by Kinjel Shah
Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.
Eli Lilly (LLY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $614.50, marking a -0.52% move from the previous day.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Top Research Reports for Amazon.com, Berkshire Hathaway & Eli Lilly
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Berkshire Hathaway Inc. (BRK.B) and Eli Lilly and Company (LLY).
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly (LLY) Stock Up 57% in 2023: Will the Uptrend Continue?
by Zacks Equity Research
Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.
Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
The latest trading day saw Eli Lilly (LLY) settling at $580.85, representing a -0.11% change from its previous close.
Why Fusion Pharmaceuticals (FUSN) Stock Was Up 14% on Wednesday
by Zacks Equity Research
Fusion Pharmaceuticals (FUSN) surges to a new record level 52-week high after analysts at Raymond James upgraded its rating following the buyout announcements for two comparable companies.
Should Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for GSEW
Is SPDR MSCI USA StrategicFactors ETF (QUS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for QUS